Sorafenib-irinotecan sequential therapy augmented the anti-tumor efficacy of monotherapy in hepatocellular carcinoma cells HepG2

Neoplasma

Volumn 62, Issue 2, 2015, Pages 172-179

  Wang, Z ^a   Zhao, Z ^b   Wu, T ^c   Song, L ^c   Zhang, Y ^c  

^a LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

^b the First Hospital of China Medical University   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Irinotecan; Sorafenib; Synergistic effect

Indexed keywords

ANNEXIN; IRINOTECAN; OXALIPLATIN; PROTEIN P53; SORAFENIB;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG DOSE SEQUENCE; FLOW CYTOMETRY; LIVER CELL CARCINOMA; MONOTHERAPY; MTT ASSAY; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84939263097     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2015_022     Document Type: Article

References (28)

1. WHO. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (accessed December 30, 2013).
2. American Cancer Society. Cancer facts and figs 2005. http://wwwcancerorg/docroot/home/indexasp (accessed October 21, 2013).
3. SONG P, FENG X, ZHANG K, SONG T, MA K et al. Screening for and surveillance of high-risk patients with HBV-related chronic liver disease: promoting the early detection of hepato­cellular carcinoma in China. Biosci Trends 2013; 7: 1–6.
4. JOHNSON PJ. Non-surgical treatment of hepatocellular carcinoma. HPB (Oxford) 2005; 7: 50–55. http://dx.doi.org/10.1080/13651820410024076
5. GAO J, FENG X, INAGAKIY, SONG P, KOKUDO N et al. Des-gamma-carboxy prothrombin and c-Met were concur­rently and extensively expressed in hepatocellular carcinoma and associated with tumor recurrence. Biosci Trends 2012; 6: 153–159. http://dx.doi.org/10.5582/bst.2012.v6.4.153
6. LLOVET JM, RICCIS MAZZAFERRO V, HILGARDP GANE E et al. Sorafenib in advanced hepatocellular car­cinoma. N Engl J Med 2008; 359: 378–390. http://dx.doi.org/10.1056/NEJMoa0708857
7. FURUSE J. Sorafenib for the treatment of unresectable hepa­tocellular carcinoma. Biologics Targets Ther 2008; 2: 779–788. http://dx.doi.org/10.2147/BTT.S3410
8. CHEN T, CHU ZH, LIU JP, WANG J, ZHAO HY et al. Ap­plication of adenosine triphosphate tumor chemosensitive assay system to individual chemotherapy for hepatocellular carcinoma. Chin J Cancer 2005; 24: 1018–1022.
9. MROSS K, STEINBILDS BAAS F, GMEHLING D, RADTKE M et al. Results from an in vitro and a clinical/pharmacological phase Istudy with the combination irinotecan and sorafenib. Eur J Cancer 2007; 43: 55–63. http://dx.doi.org/10.1016/j.ejca.2006.08.032
10. SAMALIN E, BOUCHE O, THEZENAS S, FRANCOIS E, ADENIS A et al. Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/IItrial. Br J Cancer 2014; 110: 1148–1154. http://dx.doi.org/10.1038/bjc.2013.813
11. TABERNERO J, GARCIA-CARBONERO R, CASSIDY J, SOBRERO A, VAN CUTSEM E et al. Sorafenib in combina­tion with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal can­cer: the RESPECT trial. Clin Cancer Res 2013; 19: 2541–2550. http://dx.doi.org/10.1158/1078-0432.CCR-13-0107
12. MARTINRICHARD M, GALLEGO R, PERICAY C, GARCIA FONCILLAS J, QUERALT B et al. Multicenter phase IIstudy of oxaliplatin and sorafenib in advanced gastric adenocarci­noma after failure of cisplatin and fluoropyrimidine treatment. A GEMCADstudy. Invest New Drugs 2013; 31: 1573–1579. http://dx.doi.org/10.1007/s10637-013-0020-2
13. DENT P. Multi-kinase inhibition in ovarian cancer. Cancer Biol Ther 2014; 15: 1–2. http://dx.doi.org/10.4161/cbt.26708
14. Drug label of Irinotecan Hydrochloride Injection. Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu, China.
15. Drug label of Oxaliplatin for Injection. Sanofi-Aventis France, Paris, France.
16. QIN Y, LU Y, WANG R, LIW, QU X. SL1122–37, a novel derivative of sorafenib, has greater effects than sorafenib on the inhibition of human hepatocellular carcinoma (HCC) growth and prevention of angiogenesis. Biosci Trends 2013; 7: 237–244.
17. WANG W, QIN SK, CHEN BA, CHEN HY. Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma. World J Gastroenterol 2001; 7: 702–705.
18. HOUGHTON JA, CHESHIRE PJ, HALLMAN JD, LUTZ L, LUO X et al. Evaluation of irinotecan in combina­tion with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Clin Cancer Res 1996; 2: 107–118.
19. LIU L, CAO Y, CHEN C, ZHANG X, MCNABOLA A et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851–11858. http://dx.doi.org/10.1158/0008-5472.CAN-06-1377
20. JIANG SL, WANG TX, XIANG M, ZHU SL, LIN YZ. Sensitiv­ity testing of cancer cells and TIL on chemotherapeutic drugs. Chin J Cancer. 2000; 19: 1119–1123.
21. YANG XY, YU H, PENG ZL. Involvement of ARLTS1 in chemotherapy and apoptosis in ovarian cancer cell line. Arch Gynecol Obstet 2011; 284: 1241–1246. http://dx.doi.org/10.1007/s00404-010-1782-9
22. YIP-SCHNEIDER MT, KLEIN PJ, WENTZ SC, ZENIA MENZE A et al. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. J Pharmacol Exp Ther 2009; 329: 1063–1070. http://dx.doi.org/10.1124/jpet.108.147306
23. VOUSDEN KH. p53: death star. Cell 2000; 103: 691–694. http://dx.doi.org/10.1016/S0092-8674(00)00171-9
24. LIN AW, LOWE SW. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc Natl Acad Sci U S A 2001; 98: 5025–5030. http://dx.doi.org/10.1073/pnas.091100298
25. DECKBAR D, STIFF T, KOCH B, REIS C, LOBRICH M et al. The limitations of the G1-S checkpoint. Cancer Res 2010; 70: 4412–4421. http://dx.doi.org/10.1158/0008-5472.CAN-09-3198
26. IKEGUCHIM, MAKINO M, KAIBARA N. Telomerase activity and p53 gene mutation in familial polyposis coli. Anticancer Res 2000; 20: 3833–3837.
27. BARTH SW, BRIVIBA K, WATZL B, JAGER N, MARKO Det AL. In vivo bioassay to detect irinotecan-stabilized DNA/topoisomerase Icomplexes in rats. Biotechnol J. 2010; 5: 321–327. http://dx.doi.org/10.1002/biot.200900174
28. TOMICIC MT, CHRISTMANN M, KAINA B. Topotecan-triggered degradation of topoisomerase Iis p53-dependent and impacts cell survival. Cancer Res 2005; 65: 8920–8926. http://dx.doi.org/10.1158/0008-5472.CAN-05-0266